{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:58:04Z","timestamp":1792616284138,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200189"],"award-info":[{"award-number":["82200189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2021YFA1101500"],"award-info":[{"award-number":["2021YFA1101500"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06399-1","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:58:14Z","timestamp":1743746294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed\/refractory B cell acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"23","author":[{"given":"Wenyue","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"19","key":"6399_CR1","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","volume":"143","author":"N Gokbuget","year":"2024","unstructured":"Gokbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143(19):1903\u201330.","journal-title":"Blood"},{"issue":"10230","key":"6399_CR2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146\u201362.","journal-title":"Lancet"},{"issue":"10","key":"6399_CR3","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N Gokbuget","year":"2012","unstructured":"Gokbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032\u201341.","journal-title":"Blood"},{"issue":"5","key":"6399_CR4","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.27237","volume":"99","author":"S Nishiwaki","year":"2024","unstructured":"Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, et al. Utility of allogeneic stem cell transplantation for adult Ph\u2009+\u2009ALL with complete molecular remission. Am J Hematol. 2024;99(5):806\u201315.","journal-title":"Am J Hematol"},{"issue":"26","key":"6399_CR5","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","volume":"134","author":"KJ Curran","year":"2019","unstructured":"Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood. 2019;134(26):2361\u20138.","journal-title":"Blood"},{"issue":"5","key":"6399_CR6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"9","key":"6399_CR7","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-Year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"6399_CR8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3324\/haematol.2022.280678","volume":"108","author":"AS Wayne","year":"2023","unstructured":"Wayne AS, Huynh V, Hijiya N, Rouce RH, Brown PA, Krueger J, et al. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2023;108(3):747\u201360.","journal-title":"Haematologica"},{"issue":"9","key":"6399_CR9","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"36","key":"6399_CR10","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase i\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381\u20139.","journal-title":"J Clin Oncol"},{"issue":"23","key":"6399_CR11","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1002\/cncr.32335","volume":"125","author":"EJ Jabbour","year":"2019","unstructured":"Jabbour EJ, Gokbuget N, Kantarjian HM, Thomas X, Larson RA, Yoon SS, et al. Transplantation in adults with relapsed\/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019;125(23):4181\u201392.","journal-title":"Cancer"},{"issue":"8","key":"6399_CR12","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/s41409-021-01279-w","volume":"56","author":"T Badar","year":"2021","unstructured":"Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, et al. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transpl. 2021;56(8):1998\u20132004.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"6399_CR13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41408-024-01127-2","volume":"14","author":"J Lu","year":"2024","unstructured":"Lu J, Bao X, Zhou J, Li X, He Z, Ji Y, et al. Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease. Blood Cancer J. 2024;14(1):143.","journal-title":"Blood Cancer J"},{"issue":"1","key":"6399_CR14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.16339","volume":"189","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Chen H, Song Y, Tan X, Zhao Y, Liu X, et al. Chimeric antigens receptor T cell therapy as a Bridge to Haematopoietic stem cell transplantation for refractory\/ relapsed B-cell acute lymphomalastic leukemia. Br J Haematol. 2020;189(1):146\u201352.","journal-title":"Br J Haematol"},{"issue":"1","key":"6399_CR15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41409-022-01845-w","volume":"58","author":"Z Yao","year":"2023","unstructured":"Yao Z, Gu B, Zhang Y, Qi J, Chen J, Xu Y, et al. CD19 chimeric antigen receptor T-cell therapy as a Bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transpl. 2023;58(1):103\u20135.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"6399_CR16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","volume":"135","author":"N Wang","year":"2020","unstructured":"Wang N, Hu X, Cao W, Li C, Xiao Y, Cao Y, et al. Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood. 2020;135(1):17\u201327.","journal-title":"Blood"},{"issue":"1","key":"6399_CR17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","volume":"14","author":"XH Zhang","year":"2021","unstructured":"Zhang XH, Chen J, Han MZ, Huang H, Jiang EL, Jiang M, et al. The consensus from the Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14(1):145.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"6399_CR18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","volume":"79","author":"P Ljungman","year":"2024","unstructured":"Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, et al. Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum. Clin Infect Dis. 2024;79(3):787\u201394.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6399_CR19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41409-019-0548-7","volume":"55","author":"R Al Hamed","year":"2020","unstructured":"Al Hamed R, Bazarbachi AH, Mohty M. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. Bone Marrow Transpl. 2020;55(1):25\u201339.","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"6399_CR20","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2141.2012.09114.x","volume":"157","author":"ML MacMillan","year":"2012","unstructured":"MacMillan ML, DeFor TE, Weisdorf DJ. What predicts high risk acute graft-versus-host disease (GVHD) at onset? Identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol. 2012;157(6):732\u201341.","journal-title":"Br J Haematol"},{"issue":"4","key":"6399_CR21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295\u2013304.","journal-title":"Transplantation"},{"key":"6399_CR22","doi-asserted-by":"crossref","first-page":"1237031","DOI":"10.3389\/fonc.2023.1237031","volume":"13","author":"H Pourhassan","year":"2023","unstructured":"Pourhassan H, Agrawal V, Pullarkat V, Aldoss I. Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment. Front Oncol. 2023;13:1237031.","journal-title":"Front Oncol"},{"key":"6399_CR23","doi-asserted-by":"crossref","first-page":"204062072312014","DOI":"10.1177\/20406207231201454","volume":"14","author":"HM Kantarjian","year":"2023","unstructured":"Kantarjian HM, Logan AC, Zaman F, Gokbuget N, Bargou RC, Zeng Y, et al. Survival outcomes in patients with relapsed\/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab. Ther Adv Hematol. 2023;14:20406207231201454.","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"6399_CR24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jcyt.2022.10.001","volume":"25","author":"H Xu","year":"2023","unstructured":"Xu H, Lv Q, Huang L, Cao W, Wang J, Meng F, et al. Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19\/CD22 in refractory\/relapsed transformed aggressive B-cell lymphoma. Cytotherapy. 2023;25(2):185\u201391.","journal-title":"Cytotherapy"},{"issue":"6","key":"6399_CR25","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41375-022-01561-w","volume":"36","author":"F Nguyen-Khac","year":"2022","unstructured":"Nguyen-Khac F, Bidet A, Daudignon A, Lafage-Pochitaloff M, Ameye G, Bilhou-Nabera C, et al. The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone group of hematological cytogenetics (GFCH). Leukemia. 2022;36(6):1451\u201366.","journal-title":"Leukemia"},{"issue":"5","key":"6399_CR26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jtct.2024.03.004","volume":"30","author":"A Sayyed","year":"2024","unstructured":"Sayyed A, Chen C, Gerbitz A, Kim DDH, Kumar R, Lam W, et al. Pretransplant blinatumomab improves outcomes in B cell acute lymphoblastic leukemia patients who undergo allogeneic hematopoietic cell transplantation. Transpl Cell Ther. 2024;30(5):520. e1- e12.","journal-title":"Transpl Cell Ther"},{"key":"6399_CR27","doi-asserted-by":"crossref","unstructured":"Pawinska-Wasikowska K, Wieczorek A, Balwierz W, Bukowska-Strakova K, Surman M, Skoczen S. Blinatumomab as a Bridge therapy for hematopoietic stem cell transplantation in pediatric refractory\/relapsed acute lymphoblastic leukemia. Cancers (Basel). 2022;14(2).","DOI":"10.3390\/cancers14020458"},{"issue":"1","key":"6399_CR28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41408-023-00837-3","volume":"13","author":"Y Qiu","year":"2023","unstructured":"Qiu Y, Wan CL, Xu MZ, Zhou HX, Liu MJ, Gong WJ, et al. Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL. Blood Cancer J. 2023;13(1):66.","journal-title":"Blood Cancer J"},{"issue":"5","key":"6399_CR29","first-page":"2939","volume":"110","author":"L Qin","year":"2024","unstructured":"Qin L, Li H, Zheng D, Lin S, Ren X. Glioblastoma patients\u2019 survival and its relevant risk factors during the pre-COVID-19 and post-COVID-19 pandemic: real-world cohort study in the USA and China. Int J Surg. 2024;110(5):2939\u201349.","journal-title":"Int J Surg"},{"issue":"1","key":"6399_CR30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-020-00873-7","volume":"13","author":"H Zhao","year":"2020","unstructured":"Zhao H, Wei J, Wei G, Luo Y, Shi J, Cui Q, et al. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed\/refractory acute lymphoblastic leukemia: a multi-center retrospective study. J Hematol Oncol. 2020;13(1):42.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6399_CR31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41409-018-0398-8","volume":"54","author":"I Aldoss","year":"2019","unstructured":"Aldoss I, Pullarkat V. Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD? Bone Marrow Transpl. 2019;54(1):3\u20135.","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"6399_CR32","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1002\/hem3.82","volume":"8","author":"Z Huang","year":"2024","unstructured":"Huang Z, Zhang L, Gong X, Li J, Deng S, Cai Z, et al. An integrated classification of tumor suppressor IKZF1 inactivation and oncogenic activation in Philadelphia chromosome-like acute lymphoblastic leukemia. Hemasphere. 2024;8(5):e82.","journal-title":"Hemasphere"},{"key":"6399_CR33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2016.00507","volume":"7","author":"J Ogonek","year":"2016","unstructured":"Ogonek J, Kralj Juric M, Ghimire S, Varanasi PR, Holler E, Greinix H, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:507.","journal-title":"Front Immunol"},{"issue":"2","key":"6399_CR34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jtct.2023.10.024","volume":"30","author":"G Llaurador","year":"2024","unstructured":"Llaurador G, Shaver K, Wu M, Wang T, Gillispie A, Doherty E, et al. Blinatumomab therapy is associated with favorable outcomes after allogeneic hematopoietic cell transplantation in pediatric patients with B cell acute lymphoblastic leukemia. Transpl Cell Ther. 2024;30(2):217\u201327.","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"6399_CR35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","volume":"94","author":"H Jiang","year":"2019","unstructured":"Jiang H, Li C, Yin P, Guo T, Liu L, Xia L, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial. Am J Hematol. 2019;94(10):1113\u201322.","journal-title":"Am J Hematol"},{"key":"6399_CR36","doi-asserted-by":"publisher","unstructured":"Fabrizio VA, Kernan NA, Boulad F, Cancio M, Allen J, Higman M et al. Low toxicity and favorable overall survival in relapsed\/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 2020;55(11):2160-2169. https:\/\/doi.org\/10.1038\/s41409-020-0926-1","DOI":"10.1038\/s41409-020-0926-1"},{"key":"6399_CR37","doi-asserted-by":"crossref","unstructured":"Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260-e72.","DOI":"10.1016\/S1473-3099(19)30107-0"},{"issue":"4","key":"6399_CR38","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","volume":"78","author":"E Kampouri","year":"2024","unstructured":"Kampouri E, Ibrahimi SS, Xie H, Wong ER, Hecht JB, Sekhon MK, et al. Cytomegalovirus (CMV) reactivation and CMV-Specific Cell-Mediated immunity after chimeric antigen receptor T-Cell therapy. Clin Infect Dis. 2024;78(4):1022\u201332.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"6399_CR39","doi-asserted-by":"crossref","first-page":"113263","DOI":"10.1016\/j.celrep.2023.113263","volume":"42","author":"Z Li","year":"2023","unstructured":"Li Z, Zhao L, Zhang Y, Zhu L, Mu W, Ge T, et al. Functional diversification and dynamics of CAR-T cells in patients with B-ALL. Cell Rep. 2023;42(10):113263.","journal-title":"Cell Rep"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06399-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06399-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06399-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T22:03:23Z","timestamp":1743804203000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06399-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6399"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06399-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Institutional Review Board of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Approval Number: TJ-IRB202412159).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"391"}}